Fennec Pharmaceuticals Inc. (TSX: FRX, NASDAQ: FENC), is a clinical-stage biotechnology company developing PEDMARKTM (a unique formulation of Sodium Thiosulfate (STS)), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. PEDMARKTM is being investigated in two pediatric Phase III studies to evaluate the reduction of ototoxicity and impact on survival.

Fennec Pharmaceuticals, Inc. Capital Structure

15.9million shares outstanding.

1.3million shares upon exercise at USD $1.50, warrants expire on November 22, 2018